On this page
- Quick reference
- Dosage chart and four steps
- Supplies needed
- Vial and research context
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- Sources and Further Reading
- Related research, protocols, and guides
MOTS-C Quick Reference (10 mg Vial)
- Vial contents
- 10 mg MOTS-C
- Final volume
- 3 mL
- Concentration
- 3.33 mg/mL
- One U-100 unit
- 33.33 mcg in 0.01 mL
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read MOTS-c Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
MOTS-C Dosage Chart
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 12 units (0.12 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 18 units (0.18 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 24 units (0.24 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously[7]. This schedule uses the largest practical dilution (3.0 mL) to maintain per‑injection accuracy. Stay at each dose level for approximately 2 weeks before increasing, and monitor for any adverse reactions[7].
For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light. Follow documented, formulation-specific discard guidance[14].
Supplies Needed
Plan based on an 8–12 week daily protocol with gradual titration.
-
Peptide Vials (MOTS-C, 10 mg each):
- 8 weeks: approximately 3 vials required
- 12 weeks: approximately 6 vials required
- 16 weeks: approximately 9 vials required
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL — 1 bottle required (10 mL each)
- 12 weeks (6 vials): 18 mL — 2 bottles required (10 mL each)
- 16 weeks (9 vials): 27 mL — 3 bottles required (10 mL each)
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
- 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
- 16 weeks: 224 swabs — 3 boxes required (100 swabs each)
PeptideDosages has no affiliation with Pure Lab Peptides and receives no commission from these Pure Lab links. Supplier pages are not scientific evidence or proof of suitability for human use.
MOTS-C Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); follow documented, formulation-specific discard guidance.
MOTS-c is a 16–amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation[1][2]. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline[1][4]. No clinical trials have been completed in humans to date[8]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.
Protocol Overview
Concise summary of the once‑daily regimen.
- Goal: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence[1][2][4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 200–1,000 mcg daily with gradual titration over 10 weeks.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach based on animal-to-human extrapolation.
- Start: 200 mcg daily for 2 weeks.
- Titration: Increase by ~200 mcg every 2 weeks: 400 mcg (Weeks 3–4), 600 mcg (Weeks 5–6), 800 mcg (Weeks 7–8).
- Target: Up to 1,000 mcg (1.0 mg) daily by Weeks 9–10+ if well tolerated[7].
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality and potency.
- Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); the discard interval depends on the exact formulation and product testing. General peptide stability estimates do not establish a shelf life for this vial[14].
- Aliquoting: Prepare single-use aliquots and freeze at −20 °C (−4 °F) if needed; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes for each injection; dispose in a sharps container[11].
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy[11].
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose, injection site, and any observations to maintain consistency.
- Discontinue use and consult a medical professional if any concerning symptoms arise.
How This Works
MOTS-c functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise[2]. Its primary mechanism is AMPK activation through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog)[1][2]. Activated AMPK shifts cells into an energy-efficient mode – enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis[2].
MOTS-c can also translocate to the cell nucleus under stress conditions and upregulate antioxidant and stress-response genes[2]. This retrograde signaling from mitochondria to nucleus increases expression of cytoprotective enzymes, helping cells cope with oxidative stress. Research indicates MOTS-c may also modulate mTOR and inflammatory pathways, contributing to lifespan and healthspan effects[10]. Its actions resemble those of exercise and metformin at a cellular level[2], making it of great interest for metabolic disorders, obesity, and aging research.
Potential Benefits & Side Effects
Observations from preclinical literature (no human clinical trials completed to date)[8]:
- Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; prevents diet-induced insulin resistance[1][7].
- Weight & Fat Reduction: Prevents obesity and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation[1][7].
- Post-Menopausal Metabolism: Mitigates metabolic decline in ovariectomized mice; prevents menopause-related fat gain and insulin resistance[3].
- Physical Performance: Enhances exercise capacity and counters age-related frailty; old mice ran 2× longer on treadmill tests[4][7].
- Organ Protection: Reduces liver fat accumulation, improves cardiac function, and may support cognitive function in preliminary studies[2][7].
- Bone & Immunity: Promotes osteoblast activity, inhibits osteoclast formation; modulates immune aging and protects pancreatic islet cells in autoimmune diabetes models[5][10].
- Safety: No adverse effects reported in preclinical studies; human tolerability unknown. A modified analog (CB4211) showed good tolerability in a Phase 1 trial[7].
Note: These benefits have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires clinical studies.
Lifestyle Factors
Complementary strategies for best outcomes based on MOTS-c’s metabolic mechanisms.
- Pair with a balanced, protein-forward diet tailored to energy needs.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations and AMPK signaling[4][8].
- Prioritize sleep (7–9 hours) and stress management to support mitochondrial health and recovery.
- Consider intermittent fasting or caloric restriction, which may synergize with MOTS-c’s AMPK-mediated effects.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[9][11]:
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 90° (45° if very lean) into subcutaneous tissue[11].
- Do not aspirate for subcutaneous injections; inject slowly and steadily over a few seconds[9].
- Withdraw needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
- Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and lipohypertrophy[11].
- Dispose of used syringes immediately in a proper sharps container (never reuse needles)[11].
Recommended Source
We recommend Pure Lab Peptides for high‑purity MOTS-C (10 mg).
Why Pure Lab Peptides?
- High‑purity, third‑party‑tested lots with batch Certificates of Analysis (COAs).
- Consistent, ISO‑aligned handling and documentation.
- Reliable fulfillment to maintain cold‑chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-c is an experimental compound for research use only. No clinical trials have been completed in humans. Always consult qualified healthcare providers before starting any new therapy.
Sources and Further Reading
- 1
Cell Metabolism (2015)
— The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.) - 2
Journal of Translational Medicine (2023)
— Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.) - 3
Journal of Molecular Medicine (2019)
— MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.) - 4
Nature Communications (2021)
— MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.) - 5
Frontiers in Physiology (2023)
— Role of MOTS-c in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.) - 7
Cognitive Vitality Reports (2021)
— MOTS-c (Cognitive Vitality Profile) – Alzheimer’s Drug Discovery Foundation (ADDF) - 8
USADA Spirit of Sport (2023)
— What is the MOTS-c peptide? – U.S. Anti-Doping Agency education article - 9
CDC Vaccine Administration Guidelines
— Subcutaneous route technique (angle, site selection, no aspiration) - 10
Experimental & Molecular Medicine (2025)
— Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, L’Yi S, et al.) - 11
MedlinePlus Medical Encyclopedia (2023)
— Subcutaneous (SQ) injections – Patient instructions for proper technique - 13
Pure Lab Peptides
— MOTS-C (10 mg) product page (quality and batch documentation) - 14
U.S. Food and Drug Administration
— MOTS-c bulk drug substance technical review: formulation-dependent stability and quality limitations - 13
International Journal of Molecular Sciences (2022)
— MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases (Mohtashami Z, Singh MK, Salimiaghdam N, et al.) - 14
Subcutaneous Drug Injection Review (PMC)
— Literature review of factors influencing subcutaneous injection pharmacology - 15Lee et al. (2015) : Original MOTS-C mouse experiments with exact CD-1 and C57BL/6 intraperitoneal exposures, frequencies, and durations.
- 16Reynolds et al. (2021) : Mouse physical-performance and aging experiments plus endogenous MOTS-C exercise measurements in ten healthy young men.
- 17Cognitive Vitality Reports (2021) — MOTS-c (Cognitive Vitality Profile) – Alzheimer's Drug Discovery Foundation (ADDF)
- 18U.S. Food and Drug Administration : Safety-risk page reporting that FDA had not identified human exposure data for native MOTS-C by any route.
- 19MOTS-C NOD Mouse Study (2025) : NOD mouse experiment using 0.5 mg/kg/day intraperitoneally from 7 to 18 weeks of age.
- 20Cell Metabolism (2015) — Lee C, et al. The mitochondrial‑derived peptide MOTS‑c promotes metabolic homeostasis and reduces obesity and insulin resistance (PMID: 25738459)
- 21Nature Communications (2021) — Reynolds JC, et al. MOTS‑c is an exercise‑induced mitochondrial‑encoded regulator of age‑dependent physical decline and muscle homeostasis (DOI: 10.1038/s41467-020-20790-0)
- 22Cell Metabolism (2018) — Kim KH, et al. The Mitochondrial‑Encoded Peptide MOTS‑c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress (PMID: 29983246)
- 23CDC — Subcutaneous Injection Technique (PDF diagram and site guidance)
- 24NCBI Bookshelf — Best Practices for Injections: asepsis, preparation, administration, and site rotation
- 25Rapid Communications in Mass Spectrometry (2019) — Knoop A, et al. Development of an MS‑based detection method for the mitochondrion‑derived peptide MOTS‑c in plasma for doping control (DOI: 10.1002/rcm.8337)
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
Other vial-strength protocols
Related protocols and comparisons